A US neuroscientist claims that some of the studies of the experimental agent, Simufilam (Cassava Sciences), a drug that targets amyloid beta (Aβ) in Alzheimer's disease (AD), are flawed, and, as a result, has taken his concerns to the National Institutes of Health (NIH).
Matthew Schrag, MD, PhD, department of neurology, Vanderbilt University Medical Center, Nashville, Tennessee, uncovered what he calls inconsistencies in major studies examining the drug.
; ; ; agreed to pay $17.07 million to settle federal allegations of illegal diversity, equity and inclusion (DEI) hiring practices on Friday, marking the Justice Department's first resolution unde...